UPDATE 2-Novo Nordisk launches 'strong' guidance, warns of supply constraints
Yahoo! Finance
Danish drug developer Novo Nordisk on Wednesday presented "strong" sales expectations for 2023 and announced heavy investments into its production capacity, but warned of supply constraints on its best-selling drug. Novo Nordisk, which develops diabetes and obesity drugs, said it expected "periodic supply constraints" this year, partly driven by higher than expected demand for its blockbuster diabetes drug, Ozempic, and manufacturing constraints.
Continue Reading